Accessibility Menu
Cumberland Pharmaceuticals Stock Quote

Cumberland Pharmaceuticals (NASDAQ: CPIX)

$2.33
(-12.4%)
-0.33
Price as of November 5, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$2.33
Daily Change
(-12.4%) $0.33
Day's Range
$2.29 - $2.66
Previous Close
$2.33
Open
$2.59
Beta
0.45
Volume
109,487
Average Volume
43,324
Market Cap
39.8M
Market Cap / Employee
$2.66M
52wk Range
$1.04 - $7.25
Revenue
-
Gross Margin
0.73%
Dividend Yield
N/A
EPS
-$0.21
CAPs Rating
-
Industry
Pharmaceuticals

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Cumberland Pharmaceuticals Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
CPIX+97.46%-20.88%-4.58%-84%
S&P+17.53%+93.66%+14.13%+583%

Cumberland Pharmaceuticals Company Info

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. Its products include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, Sancuso, Boxaban, Vasculan. Dyscorban, and RediTrex. The company was founded by A. J. Kazimi on January 7, 1999 and is headquartered in Nashville, TN.

News & Analysis

Financial Health

General

Q3 2025YOY Change
Revenue$8.29M-8.7%
Gross Profit$6.29M-5.3%
Gross Margin75.90%2.7%
Market Cap$46.67M158.7%
Market Cap / Employee$0.51M0.0%
Employees910.0%
Net Income-$1.95M-26.8%
EBITDA-$0.93M-17.9%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q3 2025YOY Change
Net Cash$15.20M-13.0%
Accounts Receivable$10.43M-7.8%
Inventory2.9-34.9%

Liabilities

Q3 2025YOY Change
Long Term Debt$9.84M-34.9%
Short Term Debt$0.40M-93.7%

Ratios

Q3 2025YOY Change
Return On Assets-4.67%8.5%
Return On Invested Capital-11.98%-0.8%

Cash Flow

Q3 2025YOY Change
Free Cash Flow$0.16M-64.5%
Operating Free Cash Flow$0.19M-60.6%

Valuation

MetricQ4 2024Q1 2025Q2 2025Q3 2025YoY Change
Price to Book1.342.581.751.67130.43%
Price to Sales0.871.571.191.13131.22%
Price to Tangible Book Value7.4614.884.664.214.45%
Price to Free Cash Flow TTM4.5912.067.136.9358.74%
Enterprise Value to EBITDA171.3722.4572.20-44.6361.90%
Free Cash Flow Yield21.8%8.3%14.0%14.4%-37.00%
Return on Equity-24.7%-11.7%-10.8%-13.1%-63.43%
Total Debt$20.57M$10.44M$10.34M$10.24M-52.34%

No results found

No podcast episodes available.

No results found

No transcripts available.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.